Mallinckrodt Announces Donation of Two Transport Vehicles to Coolmine Therapeutic Community (TC)
DUBLIN, Sept. 17, 2018
-- Donation Supports Purchase of Vehicles to Assist Coolmine in Providing Residential Services for Families Affected by Substance Abuse --
-- Mallinckrodt Employees Offer More than 200 Volunteer Hours in Support of Coolmine TC --
DUBLIN, Sept. 17, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced a donation to Coolmine Therapeutic Community enabling the purchase of two new transport vehicles for the centre.
Coolmine provides community, day and residential services to men and women with problematic substance use and their families in Ireland. On Monday, Mallinckrodt President and Chief Executive Officer Mark Trudeau presented the keys to those transport vehicles to Coolmine CEO Pauline McKeown.
"Mallinckrodt and Coolmine have had a long-standing relationship, and Coolmine is recognized as a leading corporate social responsibility (CSR) partner for us in Dublin," Trudeau said. "We are pleased to enable the purchase of the vehicles to help the centre meet vital transportation needs in local residential services. Mallinckrodt is committed to strengthening the communities in which our employees live and work, and our CSR activities strive to advance society in meaningful ways such as this."
The new vehicles – replacing older, unreliable minibuses – will provide transport for those served at Ashleigh House, which cares for up to 24 women and 17 children from infants to those at preschool age. Mothers and children at the facility can have particular care and medical issues that result in numerous external appointments on any given day. These include maternity, antenatal, adult and children's hospital appointments, as well as general practitioner visits. Many clients in both residential units require transport for access visits and case conferences across Ireland that help keep families together.
Additionally, the vehicles will transport clients who are mothers and fathers to educational and social family activities as part of Coolmine's Parents under Pressure scheme. They will also be utilised to accommodate transportation of clients attending day services and step down programmes from community house settings who may have childcare needs.
"Coolmine has benefitted from such a real and meaningful corporate social responsibility partnership with Mallinckrodt for the past two years, and we are deeply grateful," said McKeown. "This additional financial support is significant, allowing us access to new vehicles that will be vital for our support of clients and their families. We would not be able to bolster our service without the company's support. We are also appreciative of the volunteer hours provided by Mallinckrodt staff, which have had a lasting impact on Coolmine."
Mallinckrodt colleagues have provided more than 200 volunteer hours assisting with upgrades of Coolmine's premises, internally and externally, in addition to the company's financial support.
"Coolmine Therapeutic Community provides critical support and services for families and individuals encountering very serious challenges in their lives," said Dr. David Keenan, Managing Director of Mallinckrodt Pharmaceuticals Ireland. "On behalf of our Mallinckrodt employees in Ireland, we are very pleased to continue to support the centre in its essential work."
Coolmine has been a national drug and alcohol-treatment service provider in Ireland since 1973. We provide a range of high quality residential and non-residential services to men, women, their children and their families impacted by addiction. Our specialist programmes work with the most marginalised in Irish society. Coolmine is the only mother and child residential rehabilitation service in Ireland, catering for women with children – and pregnant women who are seeking help with addiction.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Included within the company's discontinued operations, the Specialty Generics business includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
087 337 6665
Senior Communications Manager
Chief Public Affairs Officer
Daniel J. Speciale, CPA
Investor Relations and Strategy Officer